

Thermo Fisher Scientific Life Technologies Investment UK I Limited

Annual report and financial statements for the year ended 31 December 2020

Company registration number: 09253579

THURSDAY



AAE4A5B5

A05

30/09/2021

#165

COMPANIES HOUSE

**THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I
LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR
ENDED 31 DECEMBER 2020**

Contents

Officers and Professional Advisers	3
Strategic Report for the Year Ended 31 December 2020	4
Directors' Report for the Year Ended 31 December 2020	6
Independent Auditors' report to the members of Thermo Fisher Scientific Life Technologies Investment UK I Limited	8
Financial Statements for the Year Ended 31 December 2020:	
• Profit and Loss Account	11
• Balance Sheet	12
• Statement of Changes in Equity	13
Notes to the Financial Statements for the Year Ended 31 December 2020	14 to 21
Annex A	22 to 46

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

OFFICERS AND PROFESSIONAL ADVISERS

Directors

A Smith
D Norman
E Cameron
S W Ahmed appointed 23 March 2020

Company Secretary

Oakwood Corporate Secretary Limited
R Gregg

Registered office

3rd Floor
1 Ashley Road
Altrincham, Cheshire
WA14 2DT

Bankers

Bank Mendes Gans N.V.
Herengracht 619
1017 CE Amsterdam
The Netherlands

Solicitors

Addleshaw Goddard
1 St Peter's Square
Manchester
M2 3DE

Independent auditors

PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
141 Bothwell Street
Glasgow
G2 7EQ

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The directors present their strategic report on the company for the year ended 31 December 2020.

Review of the business and future developments

The principal activity of the company is that of a holding company that does not in itself trade. The company is a wholly owned subsidiary of Thermo Fisher Scientific Inc.

There are expected to be no material changes to the operation of the company and the directors are confident that performance will continue to be in line with expectations.

Result and key performance indicators

The company's only activities are that of investment in group companies. The company provides support to group companies as required. KPI analysis is considered unnecessary for an understanding of the company's performance and position; both are which are adequately reflected in the balance sheet.

At 31 December 2020 the company had net assets of £3,825,214,000 (2019: £3,825,227,000).

The directors consider the company to be going concern due to the ongoing support of the ultimate parent company.

Section 172 statement

The directors work to promote the success of the company, by considering the impact that their decisions may have on the company, along with the company's stakeholders, having regard to the requirements of section 172 (1) (a) – (f).

The Company is a UK subsidiary of Thermo Fisher Scientific Inc., listed on the New York Stock Exchange. As the principal activity of the Company is to act as a holding company for other entities in the group, the Company has had no commercial business, employees, customers or suppliers other than transactions with other group companies during the period and, as such, the breadth of stakeholder and other considerations that would often apply in operating or commercial trading companies have generally not applied to the decisions made by the directors.

While section 172 (1) requires consideration of all stakeholders, including employees and suppliers, due to the nature of the Company's operations within the wider group, it does not have any direct employee or supplier engagement. Engagement with these stakeholders is undertaken at group level.

Principal risks and uncertainties and financial risk management

The management of the business is subject to financial risk. The mitigation of this risk has been outlined below.

Financial risk management

Given the size of the company, the directors have not delegated the responsibility of monitoring financial risk management to a sub-committee of the board and are actively involved in evaluating and monitoring the company's assets and liabilities. The policies set by the board of directors are implemented by the company's finance department. The department has a policy and procedures manual that sets out specific guidelines to manage interest rate risk, credit risk and circumstances where it would be appropriate to use financial instruments to manage these.

The key financial risk to the company is the recoverability of the value of the £3,825,235,000 investment in a number of subsidiaries. This risk is mitigated by regular impairment reviews to ensure that the subsidiary companies have suffered no material diminution in value.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Brexit

On 23 June 2016 the UK held a referendum on the UK's continuing membership of the European Union the outcome of the vote determined that the United Kingdom would leave the European Union. As a result the United Kingdom entered into a period of transition on 31 January 2020 and left the European Union on 31 December 2020. As the company is a holding company there has been no impact to date and we don't expect any future significant impact from Brexit.

COVID-19

The COVID-19 outbreak rapidly developed in 2020, with a significant number of infections causing a worldwide pandemic. Measures taken by the government to contain the virus impacted economic activity. Thermo Fisher Scientific Inc. took a number of measures to monitor, prevent and mitigate the effects of the COVID-19 virus such as safety and health measures for our people (social distancing, working from home etc.) and implementing additional protocols at our manufacturing sites to keep them operating safely. At this stage, management has determined that the impact of COVID-19 is limited due to the fact it is a holding company. The company will continue to monitor the situation and potential impact to our business.

On behalf of the Board

DocuSigned by:

231F19E0E41648D...
E Cameron

Director

17 September 2021

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

The directors present their report and the audited financial statements of the company for the year ended 31 December 2020.

Future developments

Future developments are deemed to be of strategic importance to the company and as such have been outlined within the strategic report.

Dividends

The directors do not recommend the payment of a dividend (2019: £nil).

Going concern

Thermo Fisher Scientific Inc. has indicated its intention to provide any necessary support to enable the company to continue in operational existence for the foreseeable future. To this extent, the directors have received a letter of support from Thermo Fisher Scientific Inc. confirming their financial support for a period of at least twelve months from when these financial statements are authorised for issue. Thus, the directors believe that it is appropriate for the financial statements to be prepared on the going concern basis.

Financial risk management

Disclosures relating to these areas are included in the strategic report.

Directors

The directors who held office during the year and up to the date of signing the financial statements are given below:

A Smith

D Norman

E Cameron

S W Ahmed

Appointed 23 March 2020

Third party indemnity provision

The company has made qualifying third party indemnity provisions for the benefit of its directors (which extend to the performance of any duties as a director of any associated company) and these remain in force at the date of this report.

Statement of directors' responsibilities in respect of the financial statements

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Statement of directors' responsibilities in respect of the financial statements (continued)

- select suitable accounting policies and then apply them consistently;
- state whether applicable United Kingdom Accounting Standards, comprising FRS 102, have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006.

Directors' confirmations

In the case of each director in office at the date the directors' report is approved:

- so far as the director is aware, there is no relevant audit information of which the company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Independent Auditors

The independent auditors, PricewaterhouseCoopers LLP, have indicated their willingness to continue in office.

On behalf of the Board

DocuSigned by:

E Cameron
231F19E0F41848D...

Director

17 September 2021

**THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT
UK I LIMITED
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT
UK I LIMITED**

Report on the audit of the financial statements

Opinion

In our opinion, Thermo Fisher Scientific Life Technologies Investment UK I Limited's financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2020 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual Report and Financial Statements (the "Annual Report"), which comprise: the balance sheet as at 31 December 2020; the profit and loss account, the statement of changes in equity for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic report and Directors' report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Strategic report and Directors' report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic report and Directors' report for the year ended 31 December 2020 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic report and Directors' report.

Responsibilities for the financial statements and the audit

Responsibilities of the directors for the financial statements

As explained more fully in the Statement of directors' responsibilities in respect of the financial statements, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

Based on our understanding of the company and industry, we identified that the principal risks of non-compliance with laws and regulations related to UK tax legislation, and we considered the extent to which non-compliance might have a material effect on the financial statements. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to the posting of inappropriate journal entries. Audit procedures performed by the engagement team included:

- evaluation of management's controls designed to prevent and detect irregularities;
- reviewing minutes of meetings of those charged with governance;
- enquiring of management around actual and potential litigation, claims and tax disputes;
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- scanning all journals posted during the year to confirm they were in line with our expectations of the entity and for those which were not, verifying those to appropriate audit evidence.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.



Lorraine Quinn (Senior Statutory Auditor)
for and on behalf of PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
Glasgow
20 September 2021

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 PROFIT AND LOSS ACCOUNT

		Year ended 31 December	
	Note	2020 £'000	2019 £'000
Administrative expenses		(13)	(8)
Loss before taxation		(13)	(8)
Tax on loss	7	—	—
Loss for the financial year		(13)	(8)

There is no difference between the loss for the year stated above and the total comprehensive expense for the year, therefore no separate statement of comprehensive income is presented in these financial statements.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

BALANCE SHEET

		<u>As at 31 December</u>	
	Note	2020 £'000	2019 £'000
Fixed assets			
Investments	8	3,825,235	3,825,235
Creditors: amounts falling due within one year	9	(21)	(8)
Net current liabilities		(21)	(8)
Total assets less current liabilities		3,825,214	3,825,227
Net assets		3,825,214	3,825,227
Capital and reserves			
Called up share capital	11	1	1
Share premium account		1,682,593	1,682,593
Restructuring reserve		2,094,429	2,094,429
Retained earnings		48,191	48,204
Total equity		3,825,214	3,825,227

The notes on pages 14 to 21 are an integral part of these financial statements.

The financial statements on pages 11 to 21 were authorised for issue by the board of directors on 17 September 2021 and were signed on its behalf

DocuSigned by:
Euan Cameron
331F18E0E41B4BD...

Director

Thermo Fisher Scientific Life Technologies Investment UK I Limited

Company registration number: 09253579

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

STATEMENT OF CHANGES IN EQUITY

	Called up share capital	Share premium account	Restructuring reserve	Retained earnings	Total equity
	£'000	£'000	£'000	£'000	£'000
Balance as at 1 January 2019	1	1,682,593	2,094,429	48,212	3,825,235
Loss for the financial year	—	—	—	(8)	(8)
Total comprehensive expense for the year	—	—	—	(8)	(8)
Balance as at 31 December 2019	1	1,682,593	2,094,429	48,204	3,825,227
Balance as at 1 January 2020	1	1,682,593	2,094,429	48,204	3,825,227
Loss for the financial year	—	—	—	(13)	(13)
Total comprehensive expense for the year	—	—	—	(13)	(13)
Balance as at 31 December 2020	1	1,682,593	2,094,429	48,191	3,825,214

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

1. General Information

Thermo Fisher Scientific Life Technologies Investment UK I Limited ('the company') continues to be a holding company for a group of companies involved in the development, manufacture and supply of a wide range of scientific equipment and consumables for research, clinical and industrial markets.

The company is a private company limited by shares and is incorporated in the United Kingdom and registered in England. The address of its registered office is 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT.

2. Statement of compliance

The individual financial statements of Thermo Fisher Scientific Life Technologies Investment UK I Limited have been prepared in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, 'The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland' ('FRS 102') and the Companies Act 2006.

3. Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. The company has adopted FRS 102 in these financial statements.

Basis of preparation

These financial statements have been prepared on a going concern basis, under the historical cost convention and in accordance with the Companies Act 2006 and applicable accounting standards in the United Kingdom.

The preparation of financial statements in conformity with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4.

Going concern

Thermo Fisher Scientific Inc. has indicated its intention to provide any necessary support to enable the company to continue in operational existence for the foreseeable future. To this extent, the directors have received a letter of support from Thermo Fisher Scientific Inc. confirming their financial support for a period of at least twelve months from when these financial statements are authorised for issue. Thus, the directors believe that it is appropriate for the financial statements to be prepared on the going concern basis.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

3. Summary of significant accounting policies (continued)

Exemptions for qualifying entities under FRS 102

FRS 102 allows a qualifying entity certain disclosure exemptions.

Cash flow statement and related party disclosures

The company is included in the consolidated financial statements of Thermo Fisher Scientific Inc. which are publicly available. Consequently, as the company is a 100% owned subsidiary, the company has taken advantage of the exemption, under FRS 102 paragraph 1.12(b), from preparing a statement of cash flows, on the basis that it is a qualifying entity and its ultimate parent company, Thermo Fisher Scientific Inc., includes the company's cash flows in its own consolidated financial statements. The company is also exempt under the terms of FRS 102 paragraph 33.1 from disclosing related party transactions with entities that are part of the Thermo Fisher Scientific Inc. group (see note 14).

Consolidated financial statements

The financial statements contain information about Thermo Fisher Scientific Life Technologies Investment UK I Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under section 401 of the Companies Act 2006 from the requirement to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of its ultimate parent company, Thermo Fisher Scientific Inc., a company incorporated in the United States of America (see note 15). The ultimate parent undertaking and the smallest and largest group to consolidate these financial statements is Thermo Fisher Scientific Inc., the address of the ultimate parent's registered office is 168 Third Avenue, Waltham, MA 02451, USA.

Foreign currency

(i) Functional and presentation currency

The company's functional and presentation currency is the pound sterling.

(ii) Transactions and balances

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Any gain or loss arising from a change in exchange rates subsequent to the date of the transactions would be included as an exchange gain or loss in the profit and loss account.

Non-monetary items measured at historical costs are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents and all other foreign exchange gains and losses are presented in the profit and loss account within 'Administrative expenses'.

Interest income

Interest income is recognised using the effective interest rate method.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

3. Summary of significant accounting policies (continued)

Taxation

Taxation expense for the period comprises current and deferred tax recognised in the reporting period. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case tax is also recognised in other comprehensive income or directly in equity respectively.

Current or deferred taxation assets and liabilities are not discounted.

(i) Current tax

Current tax is the amount of income tax payable in respect of the taxable profit for the year or prior years. Tax is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the period end. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

(ii) Deferred tax

Deferred tax arises from timing differences that are differences between taxable profits and total comprehensive income as stated in the financial statements. These timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.

Deferred tax is recognised on all timing differences at the reporting date except for certain exceptions. Unrelieved tax losses and other deferred tax assets are only recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Investments

Investments held as fixed assets are stated at cost less any provision for impairment. Impairment reviews are performed by the directors when there has been an indication of potential impairment.

Cash and cash equivalents

Cash and cash equivalents include bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments

The company has chosen to adopt the Sections 11 and 12 of FRS 102 in respect of financial instruments.

Financial assets

Basic financial assets, including cash and bank balances and other debtors, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

3. Summary of significant accounting policies (continued)

Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.

If there is decrease in the impairment loss arising from an event occurring after the impairment was recognised the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities

Basic financial liabilities, including accruals and loans from fellow group companies, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Offsetting

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Share Premium

The share premium account is classified as equity. The share premium account represents the value paid by the shareholder in excess of the par value of share capital issued. This account can be used to write off equity-related expenses, such as underwriting costs, and may also be used to issue bonus shares.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

3. Summary of significant accounting policies (continued)

Distributions to equity holders

Dividends and other distributions to company's shareholders are recognised as a liability in the financial statements in the period in which the dividends and other distributions are approved by the company's shareholders. These amounts are recognised in the statement of changes in equity.

Related party transactions

The company discloses transactions with related parties which are not wholly owned with the same group. It does not disclose transactions with members of the same group that are wholly owned.

4 Critical accounting judgements and estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. There are no critical accounting judgements made during the year.

(a) Critical accounting estimates and assumptions

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.

(i) Impairment of investments

This recoverability risk is mitigated by regular impairment reviews of subsidiaries and sub-subsidiaries to ensure these companies have suffered no material diminution in value or that this diminution is mitigated as far as possible.

5 Auditor remuneration

Auditors' remuneration for the company of £10,680 (2019: £4,200).

6 Employees and directors

The company had no employees or staff costs during the year (2019: nil).

The emoluments of the directors are paid by a fellow group company, Thermo Electron (Management Services) Limited, which makes no recharge to the company. The directors are directors of Thermo Electron (Management Services) Limited and a number of fellow subsidiaries and it is not possible to make an accurate apportionment of their emoluments in respect of their services to each of the subsidiaries. Their total emoluments are included in the aggregate of directors' emoluments disclosed in the financial statements of Thermo Electron (Management Services) Limited.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

7 Tax on loss

Tax expense included in profit and loss:

	2020 £'000	2019 £'000
Current tax		
UK corporation tax on profits of the period	—	—
Total current tax	—	—
Tax on loss	—	—

Reconciliation of tax charge:

The tax assessed for the year is different than the standard rate of corporation tax in the UK 19% (2019: 19.00%). The differences are outlined below:

	2020 £'000	2019 £'000
Loss before taxation	(13)	(8)
Loss before taxation multiplied by the standard rate of corporation tax in the UK	(2)	(2)
Effects of:		
Effect of group relief	2	2
Total tax charge for the year	—	—

Factors that may affect future tax charges:

In the Spring Budget 2021, the Government announced that from 1 April 2023 the corporation tax rate will increase to 25%. At the balance sheet date, the proposal to increase the rate to 25% had not been substantively enacted, substantive enactment occurred on 24 May 2021, therefore, its effects are not included in these financial statements.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

8 Investments

	Subsidiary undertakings £'000
Cost and net book value	
At 31 December 2019 and 31 December 2020	3,825,235
<hr/>	
Analysed as:	£'000
Thermo Fisher Scientific Life Holdings LLC	3,062,604
Thermo Fisher Scientific Holdings (Cayman) 1	762,631
	3,825,235
<hr/>	

No dividends were received by the subsidiary undertakings during the year (2019: £nil).

The carrying value of investments is compared to estimated recoverable amounts, represented by the value in use of the investment. The directors believe that the carrying value of the investments is supported by their underlying net assets and cash flow estimates.

The company's subsidiaries are disclosed in annex A.

9 Creditors: amounts falling due within one year

	2020 £'000	2019 £'000
Overdraft	10	—
Accruals and deferred income	11	8
	21	8
<hr/>		

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

10 Financial Instruments

The company has the following financial instruments:

	Note	2020 £'000	2019 £'000
Financial liabilities measured at amortised cost			
– Bank loans and overdrafts	9	10	—
– Other creditors	9	11	8
		21	8

11 Called up share capital

	2020 £	2019 £
Allotted and fully paid		
1,002 (2019: 1,002) ordinary shares of £1	1,002	1,002

12 Restructuring reserve

In 2018 the company was part of a global reorganization in which it acquired 13.45% of Thermo Fisher Scientific Life Holdings LLC in return for its ownership in Thermo Fisher Scientific Life Senior Holdings LLC. This transaction resulted in 2018 a gain of £2,094,429,000 through the Statement of Comprehensive Income.

13 Contingent assets and liabilities

The company is a participant in a group banking arrangement under which all surplus cash balances are held as collateral for bank facilities advanced to group members. No liability is expected to arise under this arrangement.

14 Related party transactions

See note 6 for disclosure of the directors' remuneration.

The company is exempt from disclosing other related party transactions as they are with other companies that are wholly owned within the Group.

15 Controlling parties

The immediate parent undertaking is Thermo Fisher Scientific Life Netherlands C.V. whose registered office is Takkebijsters 1, 4817 BL, Breda, The Netherlands.

The ultimate parent undertaking and controlling party is Thermo Fisher Scientific Inc. which is the largest and smallest group to consolidate these financial statements. The company is incorporated in the United States of America and its common stock is listed on the New York Stock Exchange. Copies of the financial statements of the ultimate parent company are publicly available and can be obtained from its headquarters at 168 Third Avenue, Waltham, MA 02451, USA.

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher Scientific Holdings (Cayman) I (Direct)	Cayman Islands	38,70%	TMF (Cayman) Ltd. 2nd Floor, The Grand Pavilion Commercial Centre, 802 West Bay Road, P.O. Box 10338, George Town, Grand Cayman KY1-1003, Cayman Islands
Thermo Fisher Scientific Holdings (Cayman) II	Cayman Islands	38,70%	TMF (Cayman) Ltd. 2nd Floor, The Grand Pavilion Commercial Centre, 802 West Bay Road, P.O. Box 10338, George Town, Grand Cayman KY1-1003, Cayman Islands
Thermo Fisher Scientific Cayman Investments LLC	US	38,70%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific (Luxembourg) II S.a.r.l.	Luxembourg	38,70%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific (Cayman) LLC	US	11,38%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
TFS Life Holding LLC (Direct)	US	6,19%	CAPITOL SERVICES, INC. 1675 SOUTH STATE ST, STE B DOVER DE 19901
ABII 2 Limited	UK	6,19%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire UK WA14 2DT
Acoustic Cytometry Systems, Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Acros Organics BV	Belgium	6,07%	Janssen Pharmaceuticaaan 3a, B-2440 Geel, Belgium
Affymetrix Biotech Shanghai Ltd.	China	6,19%	Room 701, Floor 7 Shanghai Central Plaza No. 381 Huai Hai Zhong Road, Lu Wan District, Shanghai 200020 PRC
Affymetrix Japan K.K.	Japan	6,19%	4-2-8 Shibaura, Minato-ku, Tokyo, Japan
Affymetrix UK, Ltd	UK	6,19%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT England
Affymetrix, Inc.	US	6,19%	C/O Capitol Services, Inc. 1675 S. State Street, Suite B Dover, Delaware 19901
Allergon AB	Sweden	6,13%	Välingevägen 309, Ängelholm, 262 92, Sweden
Ambion, Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Applied Biosystems B.V.	Netherlands	6,19%	Kwartsweg 2, 2665NN Bleiswijk Netherlands

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Applied Biosystems de Mexico S. de R.L. de C.V.	Mexico	6,19%	Av. Insurgentes Sur no. 863 Piso 9 Col. Nápoles, Del. Benito Juarez C.P. 03810, CDMX, México
Applied Biosystems International, Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Applied Biosystems Taiwan LLC	US	6,19%	C/O Capitol Services Inc., 1675 South State St, Ste B Dover DE 19901
Applied Biosystems Trading (Shanghai) Company Ltd.	China	6,19%	Room 1601, 16th Floor, No.1366 West Nanjing Road, Jingan District, Shanghai
Applied Biosystems, LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
ASPEX Corporation (dba FEI Delmont)	US	6,07%	Capitol Corporate Servcies Inc. 125 LOCUST STREET HARRISBURG PA 17101
Avocado Research Chemicals Limited	UK	6,07%	3rd Floor, 1 Ashley Road Altrincham Cheshire WA14 2DT England
BAC B.V.	Netherlands	6,19%	Huizerstraatweg 28 1411 GP Naarden Netherlands
BAC IP B.V.	Netherlands	6,19%	Huizerstraatweg 28 1411 GP Naarden Netherlands
Banner Life Sciences Holdings L.P.	Cayman Islands	0,21%	PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands
Beijing Phadia Diagnostics Co., Ltd.	China	6,13%	Room 701, Building 2, No. 28, East An Ding Men Avenue, Dongcheng District, Beijing, . China
Bender Medsystems GmbH	Austria	6,19%	Campus Vienna Biocenter 2, Viehmarktasse 2a, A1030 Vienna, Austria
Bioanalysis Labsystems, S.A.	Spain	0,61%	C/ACERO,30- 32,PTA.2,MODULO 3, Barcelona
BioTrove Corporation	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
BioTrove International, Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Bonsai Technologies - Sistemas para Biotecnologia e Industria, Unipessoal Lda	Portugal	6,07%	Rua Pedro Álvares Cabral, Edifício Euro, n.º 24, 3.º, Ietra D 2670-012 Loures, Portugal
CB Diagnostics AB	Sweden	6,07%	Box 6460, 751 37 Uppsala, Sweden

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
CB Diagnostics Holding AB	Sweden	6,07%	C/O Phadia AB, Box 6460, 751 37 Uppsala, Sweden
CB Diagnostics I AB	Sweden	6,07%	c/o GTF Arendalsvagen 16 418 78 Goteborg Sweden
CellzDirect, Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
CEPH International Corporation	US	6,07%	Ave 65 Infanteria Km13.0 Carolina, PR 00987 United States
Chemiepark Linz Betriebsfeuerwehr GmbH	Austria	2,88%	St.-Peter-Straße 25, 4021 Linz, Austria
CHK Holdings Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Compendia Bioscience, Inc.	US	6,19%	C/O Capitol Corporate Services, Inc., 186 N. Main Street, 2nd Floor, Suite 1 Plymouth, Michigan 48170
DCG Systems G.K.	Japan	6,07%	Tokyo Club Building 11F, 3-2-6 Kasunigaseki, Chiyoda-Ku, Tokyo 100-0013, Japan
DCG Systems GmbH	Germany	6,07%	Nymphenburger Str. 1, 80335 Munich, Germany
DCG Systems Korea Ltd.	Korea, Republic Of	6,07%	6th Fl, Kookmin 1st Bldg., 302 Yeongdongdae-ro, Gangnam- gu, Seoul, Korea, Republic of
Diagnostix, Ltd.	ON, Canada	6,07%	1 University Ave, 3rd Floor Toronto, ON M5J 2P1 Canada Effective From: 1 January 2021
Doe & Ingalls Limited	Ireland	6,07%	25/28 North Wall Quay Dublin 1
Doublecape Holding Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Doublecape Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
DPI Newco LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
DSM Pharmaceutical Products, Inc.	US	3,03%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
eBioscience Limited	UK	6,19%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DF

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
eBioscience SAS	France	6,19%	Address change in process. New address will be: 16, Avenue du Quebec, Parc d'Affaires, Silic, Courtaboeuf, 91140, Villebon-sur-Yvette Current: 140 bis rue de Rennes, 75006, Paris, France
Ecochem NV	Belgium	6,07%	Janssen Pharmaceuticaaan 3a, 2440 Geel Belgium
Erie Finance LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Erie N10 LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Erie N2 LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Erie N2 UK Limited	UK	6,19%	3rd Floor 1 Ashley Road Altrincham Cheshire WA14 2DT
Erie UK 1 LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Erie UK 4 Limited	UK	6,19%	3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT
FEI Asia Pacific Co., Ltd.	China	6,07%	Building F1-2 of Buliding 8 & Building 9, No. 399 Sheng Xia Road, Zhangjiang Hi-Tech Park Pudong New Area Shanghai 201210 China
FEI Australia Pty Ltd.	Australia	6,07%	C/o TMF Corporate Services (Aust) Pty Ltd, Level 9, 63 Exhibition Street, Melbourne, Victoria-3000, Australia Effective From - 7 October 2019
FEI Company	US	6,07%	C/O Capitol Corporate Services, Inc. 325 13TH STREET NE, STE. #404 SALEM, OR 97301
FEI Company Japan Ltd.	Japan	6,07%	4-12-2 Shinagawa seaside West Tower 1F, Higashishinagawa, Shinagawa-ku, Tokyo
FEI Company of USA (S.E.A.) Pte Ltd.	Singapore	6,07%	1 Jalan Kilang Timor #04-02 Pacific Tech Centre Singapore 159303
FEI CPD B.V.	Netherlands	6,07%	Achtseweg Noord 5 Gebouw AAE 5651GG Eindhoven Netherlands

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
FEI EFA International Pte. Ltd.	Singapore	6,07%	38 Beach Road, South Beach Tower, #29-11 Singapore 189767
FEI EFA, Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
FEI Electron Optics B.V.	Netherlands	6,07%	Achtseweg Noord 5 Gebouw AAE 5651GG Eindhoven Netherlands
FEI Electron Optics International B.V.	Netherlands	6,07%	Achtseweg Noord 5 Gebouw AAE 5651GG Eindhoven Netherlands
FEI Europe B.V.	Netherlands	6,07%	Achtseweg Noord 5 Gebouw AAE 5651GG Eindhoven Netherlands
FEI France S.A.S	France	6,07%	16, Avenue du Quebec Parc d'Affaires Silic Courtaboeuf 91140 Villebon-Sur-Yvette France
FEI Global Holdings C.V.	Netherlands	6,07%	Achtseweg Noord 5 Gebouw AAE 5651GG Eindhoven Netherlands
FEI Hong Kong Company Limited	Hong Kong	6,07%	31/F., Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
FEI Houston, Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 206 E. 9th Street, Suite 1300 Austin, TX 78701
Fei Italia S.r.l.	Italy	6,07%	Piazzale Luigi Cadorna 4, 20123 Milano Italia
FEI Korea Ltd.	Korea, Republic Of	6,07%	145, Gwanggyo-ro, Youngtong-Gu Suwon-si, Gyeonggi-do, Korea
FEI Melbourne Pty Ltd.	Australia	6,07%	C/o TMF Corporate Services (Aust) Pty Ltd, Level 9, 63 Exhibition Street, Melbourne, Victoria-3000, Australia Effective From - 7 October 2019
FEI Microscopy Solutions Ltd	Israel	6,07%	Hayarden 1, Kiriyat Sade Hateufa, 7019900
FEI Norway Holding AS	Norway	6,07%	C/O TMF Norway AS Tollbugata 27 0157 OSLO Postal Address C/O TMF Norway AS Postboks 2334 3003 DRAMMEN
FEI S.A.S.	France	6,07%	Quai 8.2 Hall E2 39 Rue d'armagnac 33800 Bordeaux France (as of 1 May 2019)

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
FEI Saudi Arabia, LLC	Saudi Arabia	6,07%	Thuwal-King Abdullah University, KAUST Innovation Cluster, Building 1030, Office No. 3-445 on Level 2, Saudi Arabia
FEI Servicos de Nanotecnologia Ltda.	Brazil	6,07%	Avenida Joao Cabral de Mello Neto, No. 850, bloco 02, room 1705, Barra da Tijuca 22775-056, Rio de Janeiro, Brazil
FEI Technologies Inc.	US	6,07%	c/o CAPITOL CORPORATE SERVICES, INC. 325 13TH STREET NE STE 404 SALEM, OR 97301
FEI Technology de Mexico S.A. de C.V.	Mexico	6,07%	Morones Prieto Poniente 2805-220 Lomas de San Francisco Monterrey, Nuevo Leon Mexico 64710
FEI Trading (Shanghai) Co., Ltd.	China	6,07%	Floor 3-4 Building No.8, 399 Sheng Xia road, China (Shanghai) Pilot Free Trade Zone
FEI Trondheim AS	Norway	6,07%	Stiklesedveien 1 N-7401 Trondheim Norway
FEI UK Limited	UK	6,07%	3rd Floor, 1 Ashley Road Altrincham, Cheshire WA14 2DT
Fermentas China Co., Ltd.	China	1,11%	2B, 2nd Floor, Building 4, Nan You Tian An Industrial Village, Nanshan District, Shenzhen, China 518054
Fermentas Sweden AB	Sweden	6,13%	C/O Life Technologies Europe B.V. Filial, P.O. Box 12650, 112 93 Stockholm
Fiberlite Centrifuge LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Fisher Bioblock Holding II SNC	France	6,07%	Boulevard Sébastien Brant, Parc d'Innovation, 67400 Illkirch-Gaffenstaden, France
Fisher BioPharma Services (India) Private Limited	India	6,07%	"Pharmez" Special Economic Zone, Plot #22, Matoda on National Highway - 8A, Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: to be determined at later stage Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Fisher Canada Holding ULC 1	NS, Canada	6,07%	

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Fisher Canada Holding ULC 2	NS, Canada	6,07%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: to be determined at later stage Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Fisher Canada Holding ULC 3	NS, Canada	6,07%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: to be determined at later stage Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Fisher Clinical Services (Beijing) Co., Ltd.	China	6,07%	Floor 3/4, No. 1 Building Maohua Plant, No. 1 Nancaizhen Caidasanjie, Sunyi District, Beijing
Fisher Clinical Services GmbH	Switzerland	6,07%	Steinbühlweg 69 Allschwil CH- 4123 Switzerland
Fisher Clinical Services Pte. Ltd.	Singapore	6,19%	TMF Singapore H Pte. Ltd. 38 Beach Road, South Beach Tower, #29-11 Singapore 189767
Fisher Clinical Services UK Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Fisher CLP Holding Limited Partnership	NB, Canada	6,07%	44 Chipman Hill 10th Floor, Station AP.O. Box 7289 St. John, New Brunswick, E2L 4S6T, Canada
Fisher Emergo B.V.	Netherlands	6,07%	Scheepsbouwersweg 1B, 1121 PC Landsmeer
Fisher Maybridge Holdings Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Fisher Scientific AG	Switzerland	6,07%	Neuhofstrasse 11, CH-4153 Reinach BL, Switzerland
Fisher Scientific AS	Norway	6,07%	Ullernchaussen 52 0379 Oslo, Norway
Fisher Scientific Biotech Line ApS	Denmark	6,13%	Kamstrupvej 91, Kamstrup, Roskilde DK-4000, Denmark
Fisher Scientific Company	NS, Canada	6,07%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2, Canada
Fisher Scientific Europe Holdings B.V.	Netherlands	6,07%	Takkebijsters 1, 4817 BL Breda, Netherlands
Fisher Scientific GTF AB	Sweden	6,13%	Arendalsvägen 16, 418 78 Göteborg, Sweden
Fisher Scientific Holding U.K., Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Fisher Scientific Ireland Investments Unlimited	Ireland	6,07%	25/28 North Wall Quay, Dublin 1, Ireland
Fisher Scientific Ireland Limited	Ireland	6,07%	25/28 North Wall Quay, Dublin 1, Ireland
Fisher Scientific Jersey Island Limited	Jersey	6,07%	IFC5, St Helier, Jersey JE1 1ST
Fisher Scientific Luxembourg SARL	Luxembourg	6,07%	8 - 10 Avenue de la Gare, Luxembourg, L-1610
Fisher Scientific Norway AS	Norway	6,07%	Ullernchausséen 52, 0379 Oslo
Fisher Scientific Oxoid Holdings Ltd	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Fisher Scientific Oy	Finland	6,07%	Ratastie 2, FI-01620 Vantaa, Finland
Fisher Scientific S.A.S.	France	6,07%	Parc d'Innovation, Boulevard Sebastien Brant, 67400 D'illkirch-Graffenstaden, France
Fisher Scientific S.L.	Spain	6,07%	Calle Luise I, numero 9,28031 Madrid, Spain
Fisher Scientific SRL	Belgium	6,07%	L'Avenue du Port 86C/204, 1000 Brussels
Fisher Scientific The Hague I B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Fisher Scientific The Hague II B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Fisher Scientific The Hague III B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Fisher Scientific The Hague IV B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Fisher Scientific The Hague V B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Fisher Scientific U.K., Limited	UK	6,07%	Bishop Meadow Road, Loughborough, Leicestershire, LE11 5RG, England
Fisher Scientific UK Holding Company 2	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Fisher Scientific UK Holding Company Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Fisher Scientific, Unipessoal, Lda.	Portugal	6,07%	Lagoas Park, Edificio 11, Piso 0, Lisboa, Port Salvo, 2740 Oeiras, Portugal
Fisher Worldwide Distribution SPV	Cayman Islands	6,07%	TMF (Cayman) Ltd. 2nd Floor, The Grand Pavilion Commercial Centre, 802 West Bay Road, P.O. Box 10338, George Town, Grand Cayman KY1-1003, Cayman Islands

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
FSII Sweden Holdings AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
FSII Sweden Holdings I AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
FSII Sweden Holdings II AB	Sweden	6,13%	Fisher Scientific GTF Arendalsvagen 16 418 78 Goteborg Sweden
FSUK Holdings Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
FSWH I LLC	US	6,19%	1676 South State Street Suite B Dover, DE 19901
FSWH II LLC	US	6,19%	1676 South State Street Suite B Dover, DE 19901
G. & M. Procter Limited	Scotland	6,07%	3 Fountain Drive, Inchinnan Business Park, Paisley, Renfrewshire PA4 9RF, Scotland
Gold Cattle Standard Testing Labs, Inc.	US	6,19%	C/O Capitol Corporate Services, Inc. 206 E 9th Street, Suite 1300 Austin, TX 78701
Greenville Service Company, Inc.	US	3,04%	251 Little Falls Drive, Wilmington, United States
HyClone International Trade (Tianjin) Co., Ltd	China	6,19%	No. 5 Building, No. 158 West Three Road, Tianjin, China
I.Q. (Bio.) Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
INEL Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
INEL SAS	France	6,07%	Zone Industrielle CD 405, 45410, Artenay, France
Invitrogen (Shanghai) Investment Co., Ltd.	China	6,19%	1st Floor, Building #1, No. 251 Yaohua Road China (Shanghai) Pilot Free Trade Zone
Invitrogen Argentina SA	Argentina	6,19%	Calle Francisco Iturri 1474 Ciudad Autonoma de Buenos Aires (CABA) Postal Code: C1427AED Buenos Aires, Argentina
Invitrogen BioServices India Private Limited	India	6,19%	Ground Floor, Citius, First Technology Place, No 3, Export Promotion Industrial Park Whitefield, Bangalore, 560066 India
Invitrogen Europe Limited	Scotland	6,19%	3 Fountain Drive Inchinnan Business Park Paisley Renfrewshire PA4 9RF United Kingdom

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Invitrogen Finance Corporation	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Invitrogen Holdings Limited	Scotland	6,19%	3 Fountain Drive Inchinnan Business Park Paisley Renfrewshire PA4 9RF United Kingdom
Invitrogen Holdings LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Invitrogen Hong Kong Limited	Hong Kong	6,19%	31/F., Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
Invitrogen IP Holdings, Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Invitrogen Trading (Shanghai) Co., Ltd.	China	6,19%	The West Side of the 1st Floor, Block 3, No.379, Debao Road, China (Shanghai) Free Trade Zone
Ion Torrent Systems Incorporated	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Jouan Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Kettlebrook Insurance Company Ltd.	US	6,19%	C/O Capitol Corporate Services Inc. 1188 Bishop Street, Suite 2212 Honolulu, HI 96813
Laboratoire Service International SAS	France	6,19%	6 Allée des Ecureuils, Parc Tertiaire Du Bois Dieu, 69380 Lissieu France
Laboratory Specialties Proprietary Ltd.	South Africa	6,13%	3 Susan Street Strijdom Park Randburg Gauteng 2194 South Africa
Life Technologies AS	Norway	6,19%	Aksjeselskap, Ullernchausseen 52, 0379 Oslo, Norway
Life Technologies BPD AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
Life Technologies BPD UK Limited	UK	6,13%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Life Technologies Brasil Comercio e Industria de Produtos para Biotecnologia Ltda.	Brazil	6,19%	Rua Breno Ferraz do Amaral, 408, bairro Vila Firminiano Pinto, CEP: 04124-020, São Paulo/SP

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Life Technologies Chile SpA	Chile	6,19%	Avenida Marathon N°1.315, Ñuñoa, Megacentro Marathon Santiago, Chile
Life Technologies Clinical Services Lab, Inc.	US	6,19%	C/O Capitol Corporate Services Inc, 1675 South State St, Ste B Dover, DE 19901
Life Technologies Co., Ltd.	Taiwan, Province Of China	6,19%	8F., NO.123, SEC. 2, ZHONGXIAO E. RD., ZHONGZHENG DIST., TAIPEI CITY 10058, TAIWAN (R.O.C.)
Life Technologies Corporation	US	6,19%	C/O Capitol Corporate Services Inc, 1675 South State Street, Suite B, Dover, DE 19901
Life Technologies Czech Republic s.r.o.	Czechia	6,19%	V Celnici 1031/4 Praha 1 - Nové Mesto Czech Republic 110 00
Life Technologies DaAn Diagnostics (Guangzhou) Co., Ltd.	China	3,56%	B6-B9, Area B, the 2nd Floor, Block B8, No.11 Kaiyuan Avenue, Guangzhou High-tech Industrial Development Zone
Life Technologies Europe B.V.	Netherlands	6,19%	Kwartsweg 2 2665 NN Bleiswijk Netherlands
Life Technologies Finance Limited	Scotland	6,19%	3 Fountain Drive Inchinnan Business Park Paisley Renfrewshire PA4 9RF United Kingdom
Life Technologies GmbH	Germany	6,13%	Frankfurter Str. 129b Darmstadt, D-64293, Germany
Life Technologies Holdings PTE Ltd	Singapore	6,19%	33 Marsiling Ind Estate Road 3 #07-06 Singapore, SINGAPORE 739256
Life Technologies Inc.	Canada	6,07%	C/O TMF Canada Inc. 1 University Ave, 3rd Floor Toronto, ON M5J 2P1 Canada
Life Technologies Japan Ltd.	Japan	6,13%	4-2-8 Shibaura, Minato-ku, Tokyo
Life Technologies Limited	Hong Kong	6,19%	31/F., Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong.
Life Technologies Magyarország Kft	Hungary	6,19%	Váci ut 41-43 1134 Budapest Hungary
Life Technologies Norway Investments US LLC	US	6,19%	C/O Capitol Service, Inc. 1675 South State Street Ste. B Dover, DE 19901
Life Technologies Polska SP. Zoo.	Poland	6,19%	ul. Bonifraterska 17 00-203 Warszawa Poland
Life Technologies S.A.	Spain	6,19%	Avenida de la Vega 1 Edificio Veganova, ED Alcobendas, Madrid Spain

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Life Technologies S.A.S.	France	6,19%	Parc D'Affaires Silic, 16 Avenue du Quebec, 91140 Villebon-sur-Yvette, Courtaboeuf, France
Life Technologies s.r.o.	Slovakia	6,19%	Laurinska Street No. 18, Bratislava, SK 811 01, Slovakia
Linkage Biosciences S.a.r.l	Switzerland	6,07%	Chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates, Switzerland
LTC Tech South Africa (Pty) Ltd	South Africa	6,13%	200 Smit Street Fairlands Johannesburg Gauteng 2196 South Africa
MATRIX MicroScience Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Maybridge Chemical Holdings Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT England
Maybridge Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Molecular Probes, Inc.	US	6,19%	C/O Capitol Corporate Services, Inc., 325 13th Street NE, Ste. #404, Salem, OR 97301
Nanjing WeiKangLe Trading Industrial Co., Ltd.	China	6,13%	Room 1103, South Tower of Nanjing International Center, No. 201 zhongyang Road, Zhonggulou Plaza, Nanjing, Jiangsu Province, China
NewcoGen-PE LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Nihon Dynal K.K.	Japan	3,71%	Minato-Ku Tokyo 105, Yashima Bldg 2-7-14 Toranomon, Japan
Oxoid (Ely) Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Oxoid 2000 Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Oxoid A/S	Denmark	6,07%	Kamstrupvej 91, Kamstrup, Roskilde 4000 Denmark
Oxoid Australia Pty. Limited	Australia	6,07%	C/o TMF Corporate Services (Aust) Pty Ltd, Level 9, 63 Exhibition Street, Melbourne, Victoria-3000, Australia Effective From - 7 October 2019

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Oxoid Company	NS, Canada	6,07%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: to be determined at later stage Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
OXOID CZ s.r.o.	Czechia	6,07%	Kastanova 539/64, 620 00 Brno, Czech Republic
Oxoid Holding SAS	France	6,07%	Route du Paisy, Zone Industrielle, 69570 Dardilly, France
Oxoid Holdings Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Oxoid Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Oxoid International Limited	UK	6,07%	Basingstoke, Hands RG24 8PW United Kingdom
Oxoid Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Oxoid Limited (Ireland)	Ireland	6,07%	25/28 North Wall Quay, Dublin 1, Ireland
Oxoid NV	Belgium	6,07%	1702 Groot-Bijgaarden Pontbeekstraat 2 Belgium
Oxoid Pension Trustees Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT
Oxoid Senior Holdings Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham
Oxoid UKH LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Panomix SRL	Italy	6,19%	Via Roma 114/A CAP 20096 - Pioltello (MI)
Panomix, L.L.C.	US	6,19%	3420 Central Expressway Santa Clara, California 95051
Pasteur U.S. Corporation	US	6,13%	c/o Capitol Services, Inc. 1675 South State Street, Ste B. Dover, DE 19901
Patheon API Inc.	US	6,07%	C/O Capitol Corporate Services, Inc., 2 Office Park Ct., Ste. #103, Columbia, SC 29223
Patheon API Manufacturing Inc.	US	6,07%	C/O Capitol Corporate Services, Inc., 2 Office Park Ct., Ste. #103, Columbia, SC 29223

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Patheon API Services Inc.	US	6,07%	C/O Capitol Corporate Services, Inc., 2 Office Park Ct., Ste. #103, Columbia, SC 29223
Patheon Austria GmbH & CoKG	Austria	6,07%	St. Peter Straße 25, 4020 Linz, Austria
Patheon B.V.	Netherlands	6,07%	4817 BL Breda, Takkebijsters 1, The Netherlands
Patheon Banner U.S. Holdings Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon Biologics (NJ) LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon Biologics Australia Pty Ltd	Australia	6,07%	c/o TMF Corporate Services (Australia) Pty Ltd, 201 Elizabeth St, Level 16 Sydney, NSW 2000
Patheon Biologics B.V.	Netherlands	6,07%	Zuiderweg 722, 9744AP Groningen
Patheon Biologics LLC	US	6,07%	C/O Capitol Corporate Services Inc., 2 Office Park Court, Suite 103, Columbia, SC 29223
Patheon Calculus Merger LLC	US	6,07%	c/o Capitol Services 1675 South State Street, Suite B Dover, DE 19901
Patheon Cooperatief U.A.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Patheon Development Services Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon Finance LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon France SAS	France	6,07%	40 Boulevard de Champaet 38300 Bourgoin-Jallieu, France
Patheon Holdings B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Patheon Holdings I B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Patheon Holdings II B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Patheon Holdings SAS	France	6,07%	40 Boulevard de Champaret 38300 Bourgoin-Jallieu, France
Patheon I B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Patheon I Holding GmbH	Austria	6,07%	St. Peter Strasse 25, 4020 Linz, Austria
Patheon Inc.	Canada	6,07%	C/O TMF Canada Inc- 1 University Ave, 3rd Floor Toronto, ON M5J 2P1, Canada
Patheon Italia S.p.A.	Italy	6,07%	Viale GB Stucchi 110, 201900 Monza
Patheon K.K.	Japan	6,07%	Wakamatsu Bldg. 7F, 3-6 Nihonbashihoncho 3-chome, Chuo-ku, Tokyo
Patheon Life Science Products International GmbH	Austria	6,07%	St. Peter Strasse 25, 4020 Linz, Austria
Patheon Manufacturing Services LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon Pharmaceuticals Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon Pharmaceuticals Services Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon Puerto Rico Acquisitions Corporation	Puerto Rico	6,07%	c/o Edge Legal Strategies P.S.C. 252 Ave. Ponce de León Suite 1200 San Juan, Puerto Rico 00918
Patheon Puerto Rico, Inc.	Puerto Rico	6,07%	c/o Edge Legal Strategies P.S.C. 252 Ave. Ponce de León Suite 1200 San Juan, Puerto Rico 00918
Patheon Regensburg GmbH	Germany	6,07%	Donaustauer Str. 378, 93055 Regensburg, Germany
Patheon Softgels B.V.	Netherlands	6,07%	Posthoornstraat 7, 5048AS Tilburg
Patheon Softgels Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon U.S. Holdings Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon U.S. Holdings LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Patheon UK Limited	UK	6,07%	Kingfisher Drive, Swindon, Wiltshire SN3 5BZ
Patheon UK Pension Trustees Limited	UK	6,07%	3rd Floor, 1 Ashley Road Altrincham, Cheshire WA14 2DT England

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Perbio Science (Canada) Company	NS, Canada	6,07%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: 28 April 2020 Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Perbio Science AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
Perbio Science BV	Belgium	6,07%	Havanlaan 86C Box 204 1000 Brussels
Perbio Science France SAS	France	6,07%	Parc D'Affaires Silic, 16 Avenue du Quebec, 91140 Villebon-sur-Yvette, France
Perbio Science International Netherlands BV	Netherlands	6,13%	Takkebijsters 1, 4817BL Breda, Netherlands
Perbio Science Invest AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
Perbio Science Nederland B.V.	Netherlands	6,13%	Kwartsweg 2, 2665NN Bleiswijk
Perbio Science Projekt AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
Perbio Science Sweden Holdings AB	Sweden	6,13%	Postbus 183, Horby 24222, Sweden
Perbio Science UK Limited	UK	6,13%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Percivia LLC	US	3,04%	Corporation Trust Center 1209 Orange Street Wilmington, DE 19801 USA
Phadia AB	Sweden	6,13%	UPPSALA 751 37 CEP 6460 Sweden
Phadia Diagnosticos Ltda	Brazil	6,13%	Rua Vereador Germano Luiz Vieira 500, Armazém 3 Parte 3-E Itaipava – Itajaí/Santa Catarina, Brazil
Phadia Holding AB	Sweden	6,13%	Box 6460, 751 37 Uppsala, Sweden
Phadia International LLC	US	4,28%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Phadia Luxembourg Holdings S.à.r.l.	Luxembourg	6,13%	8 - 10 Avenue de la Gare, Luxembourg, L-1610
Phadia Real Property AB	Sweden	6,13%	Box 6460, 751 37 Uppsala, Sweden
Phadia s.r.o.	Czechia	6,13%	Freyova 82/27, 190 00 Prague 9, Czech Republic
Phadia Sweden AB	Sweden	6,13%	Box 6460, 751 37 Uppsala, Sweden

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Phadia Taiwan Inc.	Taiwan, Province Of China	6,07%	Suite 6F-1, No. 85 Jhouzih Street Taipei City 11493 Taiwan, Province Of China
Phadia US Inc.	US	6,13%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Phadia US Market Holdings LLC	US	6,13%	1675 SOUTH STATE ST, STE B DOVER DE 19901
Pharmacaps Mexicana S.A. de C.V.	Mexico	6,07%	Circuito Centro Cívico No. 27 Col. Ciudad Satélite Naucalpan de Juarez, Estado de México México C.P. 53100
Power Sweden Holdings I AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
Power Sweden Holdings II AB	Sweden	6,13%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
Prionics France SAS	France	6,19%	Parc d'Affaires Silic, Courtaboeuf, 16 Avenue du Quebec, 91140, Villebon-sur- Yvette, France
Prionics Italy Srl	Italy	6,19%	Viale Bianca Maria n.28 , 20122 Milan , Italy
Prionics Lelystad B.V.	Netherlands	6,19%	Platinastraat 33, Lelystad, 8211AR, Netherlands
Prionics USA Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Remel Europe Limited	UK	6,19%	3rd Floor 1 Ashley Road Altrincham, Cheshire WA14 2DT England
REP GBP I-B Blocker, Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Riogenix SA	Brazil	1,23%	Rua VISCONDE DE PIRAJA 623, 9 Andar Parte, Rio de Janeiro, Brazil
S.C.I. du 10 rue Duguay Trouin	France	6,07%	10 Rue Duguay Trouin, Saint- Herblain 44800, France
SCI INNO 92	France	6,07%	Saint-Herblain 44800, France
Shanghai Life Technologies Biotechnology Co. Ltd.	China	6,19%	No.2715, Longwu Road, Xuhui District, Shanghai
STC Bio Manufacturing, Inc	US	6,19%	C/O Capitol Corporate Services Inc. 1315 W Lawrence Avenue Springfield, Illinois 62704
Sterilin Limited	UK	6,07%	3rd Floor 1 Ashley Road Altrincham, Cheshire, WA14 2DT England

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Stokes Bio Limited	Ireland	6,19%	25/28 North Wall Quay, Dublin 1, Ireland
Sweden DIA (Sweden) AB	Sweden	6,13%	C/O Phadia AB, Box 6460, 751 37 Uppsala, Sweden
TFS FEI Holding LLC	US	6,07%	1675 South State Street Suite B Dover, DE 19901
TFS Venture Holdigns I LLC	US	6,07%	1675 South State Street Suite B Dover, DE 19901
Thermo Cayman USC Ltd.	Cayman Islands	6,07%	2nd Floor, The Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman KY1-1003, Cayman Islands
Thermo CIDTEC Inc.	US	6,07%	C/O Capitol Corporate Services, Inc., 1218 Central Avenue, Ste. #100, Albany, NY 12205
Thermo CN Luxembourg LLC	US	6,07%	1675 South State Street, Suite B Dover, DE 19901
Thermo Electron Holdings SAS	France	6,07%	4 rue Edith Piaf, Immeuble Astoria C 44800 St Herblain, France
Thermo Electron Industries	France	6,07%	4 rue Edith Piaf, Immeuble Asturia, C44800 Saint Herblain
Thermo Electron LED SAS	France	6,07%	Euptouyou Nantes Work Center, 4 rue Edith Piaf, Immeuble Asturia C, 44800, Saint Herblain (as of 8th of June 2020)
Thermo Electron SAS	France	6,07%	Parc d'Affaires SILIC, 16 Avenue du Quebec, 91140 Villebon-sur-Yvette, France
Thermo Fisher (CN) Luxembourg Holding S.à.r.l.	Luxembourg	6,07%	8-10 Avenue de la Gare, L-1610, Luxembourg
Thermo Fisher (CN) Luxembourg S.a.r.l.	Luxembourg	6,07%	8-10 Avenue de la Gare, L-1610, Luxembourg
Thermo Fisher (CN) Malta Holdings Limited	Malta	6,07%	Level 1, LM Complex Brewery Street Mriehel Birkirkara BKR 3000 Malta
Thermo Fisher (CN) Malta Holdings Ltd	Malta	6,19%	Level 1, LM Complex, Brewery Street, Mriehel BKR3000, Malta
Thermo Fisher (CN-I) Luxembourg LLC	US	6,07%	c/o Capitol Services, Inc., 1675 South State St., Ste B, Dover, Delaware 19901
Thermo Fisher (CN-II) Luxembourg LLC	US	6,07%	c/o Capitol Services, Inc., 1675 South State St., Ste B, Dover, Delaware 19901
Thermo Fisher (FEI) Ireland Limited	Ireland	6,07%	25-28 North Wall Quay, Dublin 1
Thermo Fisher (Heysham) Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altincham, Cheshire WA14 2DT England

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher (Kandel) GmbH	Germany	6,07%	Geschäftsanschrift: Zeppelinstr. 7b, 76185 Karlsruhe, Germany
Thermo Fisher Bioprocessing Research and Development (Shanghai) Co., Ltd.	China	6,19%	A202 Room, Building #1, No 1976, Gaoke Middle Road, China (Shanghai) Free Trade Zone
Thermo Fisher CHK Holding LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover, Delaware 19901
Thermo Fisher CM II LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Diagnostics AB	Sweden	6,07%	c/o Fisher Scientific GTF, Arendalsvägen 16, 418 78 Göteborg, Sweden
Thermo Fisher Diagnostics AG	Switzerland	6,07%	Zurlindenstrasse 3, Postfach 1730, Pratteln, CH - 4133, Switzerland
Thermo Fisher Diagnostics Aps	Denmark	6,07%	Gydevang 33, 3450 Allerød, Denmark
Thermo Fisher Diagnostics AS	Norway	6,07%	Ullernchaussén 52, 0379 Oslo, Norway
Thermo Fisher Diagnostics Austria GmbH	Austria	6,07%	BIG BIZ B, Dresdner Straße 89, 1200 Wien, Austria
Thermo Fisher Diagnostics B.V.	Netherlands	6,07%	Scheepsbouwersweg 1 B, 1121PC Landsmeer. Postal address: Postbus 122, 1120AC Landsmeer
Thermo Fisher Diagnostics K.K.	Japan	6,07%	4-2-8 Shibaura, Minato-ku, Tokyo
Thermo Fisher Diagnostics Limited	UK	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Thermo Fisher Diagnostics NV	Belgium	6,07%	Guldensporenpark 26, 9820 Merelbeke, Belgium Effective from 14 September 2019
Thermo Fisher Diagnostics Oy	Finland	6,07%	Ratastie 2, FI-01620 Vantaa, Finland
Thermo Fisher Diagnostics S.p.A.	Italy	6,07%	Strada Rivoltana, KM.4, 20090 Rodano, (MI) Italy
Thermo Fisher Diagnostics SAS	France	6,07%	Route de Paisy, Zone Industrielle, 69570 Dardilly, France
Thermo Fisher Diagnostics, S.L.U.	Spain	6,07%	Carretera de l'Hospitalet 147, CityPark, Edificio Londres 3ª Planta, 08940 Cornellà de Llobregat.
Thermo Fisher Diagnostics, Sociedade Unipessoal Lda	Portugal	6,07%	Lagoas Park, Edificio 11, Piso 0, Lisoa, Port Salvo, 2740 270 Oeiras, Portugal

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher Financial Services B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands
Thermo Fisher Insurance Holdings Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Insurance Holdings LLC	US	4,51%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Investments (Cayman) LLC	US	5,62%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Israel Ltd.	Israel	6,19%	Hayarden 1, Kiriyat Sade Hateufa, 7019900
Thermo Fisher RE I Corporation	US	1,21%	1675 SOUTH STATE ST, STE B DOVER DE 19901
Thermo Fisher RE II Corporation	US	1,21%	1675 SOUTH STATE ST, STE B DOVER DE 19901
Thermo Fisher Scientific (DPI) LP	Canada	6,07%	Stewart McKelvey 44 Chipman Hill 10th Floor P.O. Box 7289 Suite 1000 Station A Saint John, New Brunswick E2L 4S6
Thermo Fisher Scientific (Finance I) S.a.r.l.	Luxembourg	5,99%	8-10, Avenue de la Gare, L- 1610 Luxembourg
Thermo Fisher Scientific (Finance II) S.a.r.l.	Luxembourg	6,07%	8-10, Avenue de la Gare, L- 1610 Luxembourg
Thermo Fisher Scientific (Finance III) LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific (Finance III) S.a.r.l.	Luxembourg	6,07%	8-10, Avenue de la Gare, L- 1610 Luxembourg
Thermo Fisher Scientific (Guangzhou) Co., Ltd.	China	6,19%	Unit 204, 2nd Floor, North Tower Panorama Xinghui Square, No.36 & 38 3rd Huanyu Road, Guangzhou International Biological Island, Huangpu District, Guangzhou
Thermo Fisher Scientific (IVGN) B.V.	Netherlands	6,19%	Takkebijsters 1, 4817BL Breda, Netherlands
Thermo Fisher Scientific (IVGN) Limited	Hong Kong	6,19%	31/F., Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
Thermo Fisher Scientific (Panama) B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL, Breda, Netherlands
Thermo Fisher Scientific (Panama) Dutch LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific (Panama) II B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL Breda, Netherlands

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher Scientific (PN) Austria Holding GmbH	Austria	6,07%	Dresdner Strasse 89 1200 Wien Austria
Thermo Fisher Scientific (PN) UK Limited Partnership	UK	6,07%	1675 South Street, Suite B, Dover, DE, 19901 USA C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific (PN) UK LLC	US	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT
Thermo Fisher Scientific (PN1) UK Ltd	UK	6,07%	TMF/Trident Corp.Svcs. (Barbados) :td. Barbados Ste. 1, Ground floor, Financial Services Center, Bishop's Court Hill, St. Michael, Barbados, BB 14004
Thermo Fisher Scientific (PN-I) SRL	Barbados	6,07%	TMF/Trident Corp.Svcs. (Barbados) :td. Barbados Ste. 1, Ground floor, Financial Services Center, Bishop's Court Hill, St. Michael, Barbados, BB 14004
Thermo Fisher Scientific (PN-II) SRL	Barbados	6,07%	No. 158/6 Aneekvanich Building, 6th Floor, Room B, D, Soi Sukhumvit 55, Sukhumvit Road North Klongton Sub-disttict, WattanaDistrict, Bangkok
Thermo Fisher Scientific (Thailand) Co., Ltd.	Thailand	6,19%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT
Thermo Fisher Scientific AU II Limited	UK	6,19%	Takkebijsters 1, 4817BL Breda Netherlands
Thermo Fisher Scientific B.V.	Netherlands	6,07%	V.A. Graciuno 8, LT-02241, Vilnius, Lithuania
Thermo Fisher Scientific Baltics UAB	Lithuania	1,13%	Ludwigstraße 5b, 38106 Braunschweig, Germany
Thermo Fisher Scientific Beteiligungsverwaltungs GmbH	Germany	6,07%	Vlastimila Pecha 1282/12 627 00 Brno
Thermo Fisher Scientific Brno s.r.o.	Czechia	6,07%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: 28 April 2020 Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Thermo Fisher Scientific Canada Financing 1 ULC	NS, Canada	6,07%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: 28 April 2020 Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Thermo Fisher Scientific Canada Financing 2 ULC	NS, Canada	6,07%	

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher Scientific Canada Financing 3 ULC	NS, Canada	6,07%	Stewart McKelvey Queen's Marquee 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: 28 April 2020 Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Thermo Fisher Scientific CMN LLC	US	5,62%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Colombia S.A.S	Colombia	6,19%	Carrera 4 No. 72-35, Bogota, Colombia
Thermo Fisher Scientific Denmark Senior Holdings ApS	Denmark	1,87%	Kamstrupvej 91, Kamstrup, Roskilde 4000, Denmark
Thermo Fisher Scientific Falcon Senior Holdings Inc.	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific FLC B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL, Breda, Netherlands
Thermo Fisher Scientific FLC Hong Kong Limited	Hong Kong	6,07%	27th Floor, Neich Tower, 128 Gloucester Road, Wanchai, Hong Kong
Thermo Fisher Scientific FLC II B.V.	Netherlands	6,07%	Takkebijsters 1, 4817BL, Breda, Netherlands The Company's registered office in the State of Delaware is: 1675 South State Street Suite B City of Dover County of Kent 19901 USA Registered agent: Capitol Services Inc.
Thermo Fisher Scientific FSUKHCO Financing (Barbados) SRL	Barbados	6,07%	TMF/Trident Corp.Svcs. (Barbados) :td. Barbados Ste. 1, Ground floor, Financial Services Center, Bishop's Court Hill, St. Michael, Barbados, BB 14004
Thermo Fisher Scientific GENEART GmbH	Germany	6,13%	Im Gewerbepark B35 Regensburg 93059 Germany
Thermo Fisher Scientific India Pvt Ltd	India	0,16%	403-404, B Wing, Delphi, Hiranandani Business Park, Powai, Mumbai 400072 India
Thermo Fisher Scientific Investments (Luxembourg) S.à.r.l.	Luxembourg	6,13%	8-10 Avenue de la Gare Luxembourg, L-1610
Thermo Fisher Scientific Investments (Sweden) II LLC	US	4,28%	c/o Capitol Services, Inc. 1675 South State Street, Ste. B Dover, DE 19901
Thermo Fisher Scientific Investments (Sweden) S.A.R.L.	Luxembourg	1,87%	8-10 Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific Invitrogen Financing (Barbados) SRL	Barbados	6,19%	TMF/Trident Corp.Svcs. (Barbados) :td. Barbados Ste. 1, Ground floor, Financial Services Center, Bishop's Court Hill, St. Michael, Barbados, BB 14004

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher Scientific Life Canada Holding ULC	NS, Canada	6,13%	Stewart McKelvey Queen's Marque 600-1741 Lower Water Street Halifax, N.S. B3J 0J2 Effective From: 8 July 2020 Mailing address: Stewart McKelvey P.O. Box 997, Halifax, N.S. B3J 2X2
Thermo Fisher Scientific Life CV GP Holdings II LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Life Enterprises C.V.	Netherlands	6,19%	Takkebijsters 1, 4817 BL Breda Netherlands
Thermo Fisher Scientific Life Enterprises GP LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Life International GP Holdings LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Life International Holdings I C.V.	Netherlands	6,19%	Takkebijsters 1, 4817 BL Breda Netherlands
Thermo Fisher Scientific Life International Holdings II C.V.	Netherlands	6,19%	Takkebijsters 1, 4817 BL Breda Netherlands
Thermo Fisher Scientific Life Investments II S.à.r.l.	Luxembourg	6,13%	8 - 10 Avenue de la Gare, Luxembourg, L-1610
Thermo Fisher Scientific Life Investments US Financing II LLC	US	6,13%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Life Netherlands Holding C.V.	Netherlands	6,19%	Takkebijsters 1, 4817 BL Breda, Netherlands
Thermo Fisher Scientific Life NL Holdings GP LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Life Senior Holdings, Inc.	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Life Tech Korea Holdings LLC	US	6,19%	C/O CAPITOL SERVICES, INC., 1675 S STATE ST STE B, DOVER, DE 19901
Thermo Fisher Scientific Life Technologies Enterprise Holding Limited	UK	6,19%	3rd Floor, 1 Ashley Road Altrincham, Cheshire, WA142DT England
Thermo Fisher Scientific Life Technologies Investment UK I Limited	UK	6,19%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Thermo Fisher Scientific Life Technologies Israel Investment I Limited	UK	6,19%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher Scientific Life Technologies Israel Investment II Limited	UK	6,19%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, England
Thermo Fisher Scientific Life Technologies Luxembourg Holdings LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Luxembourg Enterprise Holdings S.à r.l.	Luxembourg	6,19%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific Luxembourg Life Technologies UK Holding S.à r.l.	Luxembourg	6,19%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific Luxembourg Venture Holdings I S.à r.l.	Luxembourg	6,07%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific Luxembourg Venture Holdings II S.à r.l.	Luxembourg	6,07%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific Milano Srl	Italy	6,07%	Strada Rivoltana SNC, 20090 Rodano (MI)
Thermo Fisher Scientific Norway Holdings AS	Norway	6,19%	Ullernchausséen 52, 0349 Oslo
Thermo Fisher Scientific Norway Senior Holdings AS	Norway	6,19%	Ullernchausséen 52, 0349 Oslo, Norway
Thermo Fisher Scientific Norway US Investments LLC	US	6,19%	C/o Capitol Services, Inc 1675 South State Street Suite B Dover, DE 19901
Thermo Fisher Scientific Panama I Cayman Ltd.	Cayman Islands	6,07%	TMF (Cayman) Ltd. 2nd Floor, The Grand Pavilion Commercial Centre, 802 West Bay Road, P.O. Box 10338, George Town, Grand Cayman KY1-1003, Cayman Islands
Thermo Fisher Scientific PN2 (Luxembourg) S.a.r.l.	Luxembourg	6,07%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific PN2 (Malta) Limited	Malta	6,06%	Lével 1, LM Complex, Brewery Street, Mriehel BKR3000, Malta
Thermo Fisher Scientific PN2 C.V.	Netherlands	6,07%	Takkebijsters 1, 4817 BL, Breda, Netherlands
Thermo Fisher Scientific PN2 LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific PNM Limited Liability Partnership	United Kingdom	6,07%	3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT
Thermo Fisher Scientific PNM S.a.r.l.	Luxembourg	6,07%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific PRB S.a.r.l.	Luxembourg	6,13%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific Re Ltd.	Bermuda	1,21%	3rd Floor, Par La Ville Place, 14 Par La Ville Road, Hamilton HM 08, Bermuda Effective from 22 November 2019

THERMO FISHER SCIENTIFIC LIFE TECHNOLOGIES INVESTMENT UK I LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020 – Annex A

Legal entity name	Country	% held	Registered address
Thermo Fisher Scientific Senior Holdings LP	NB, Canada	6,07%	Stewart McKelvey 44 Chipman Hill 10th Floor P.O. Box 7289 Suite 1000 Station A Saint John, New Brunswick E2L 4S6
Thermo Fisher Scientific Senior Holdings US LP	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Scientific Solutions LLC	Korea, Republic Of	6,19%	11, 12 fl, 281, Gwangpyung-ro, Gangnam-gu, Seoul
Thermo Fisher Scientific Sweden Holdings S.a.r.l.	Luxembourg	6,13%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific TDI S.a.r.l. (Luxembourg)	Luxembourg	6,07%	8-10, Avenue de la Gare, L-1610 Luxembourg
Thermo Fisher Scientific Worldwide Investments LLC	US	5,06%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Fisher Senior Canada Holdings LLC	US	6,07%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo MF Physics LLC	US	5,88%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Optek S.A.	Spain	6,07%	AVENIDA VALDELAPARRA, 27 EDIFICIO ALCOR PLANTA 2, Alcobendas, Madrid
Thermo Patheon Holdings LLC	US	6,19%	C/O Capitol Corporate Services Inc., 1675 South State St, Ste B Dover DE 19901
Thermo Quest S.A.	Spain	6,07%	AV. DE VALDELAPARRA 27, EDF. ALCOR, PL 2, Alcobendas, Madrid
Thermo Scientific Microbiology Pte. Ltd.	Singapore	6,07%	TMF Singapore H Pte. Ltd. 38 Beach Road, South Beach Tower, #29-11 Singapore 189767
Thermo Scientific Microbiology Sdn. Bhd.	Malaysia	6,07%	10th Floor, Menara Hap Seng, No. 1 & 3, Jalan P.Ramlee, 50250 Kuala Lumpur
Thermo USC I LLC	US	5,06%	c/o Capitol Services, Inc. 1675 South State Street, Ste. B Dover, DE 19901
USB Corporation	US	6,19%	c/o Capitol Corporate Services, Inc., 4568 Mayfield Road, Suite 204, Cleveland, Ohio 44121
Westover Scientific, Inc.	US	6,19%	C/O Capitol Services, Inc. 1780 Barnes Blvd. SW Tumwater, Washington 98512